Silexion Therapeutics Corp. (NASDAQ: SLXN) received approval from the Israeli Ministry of Health to begin a Phase 2/3 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE